PBM
IVA

Propel Bio Management’s Inventiva IVA Stock Holding History

Propel Bio Management’s Portfolio IVA Stock Details IVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.84M Buy
1,281,212
+556,534
+77% +$2.67M 2.53% 14
2026
Q1 		$3.99M Sell
724,678
-275,322
-28% -$1.68M 2.52% 13
2025
Q4 		$4.65M Buy
+1,000,000
New +$4.65M 3.97% 8

Other funds holding IVA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

Propel Bio Management's IVA Position: Q2 2026 in Review

Propel Bio Management increased its Inventiva (IVA) stake by 77% in Q2 2026, buying an estimated $2.67M and bringing the position to 1,281,212 shares worth $4.84M. The position accounts for 2.53% of the portfolio, ranked #14.

Propel Bio Management first reported a position in IVA in Q4 2025 and has held it in 3 quarters since. 88 funds tracked by Wall St. Rank hold IVA as of Q2 2026.

  • Propel Bio Management held 1,281,212 shares of Inventiva worth $4.84M as of Q2 2026.
  • Propel Bio Management bought 556,534 Inventiva shares in Q2 2026, an estimated $2.67M.
  • Inventiva made up 2.53% of Propel Bio Management's portfolio in Q2 2026, its #14 holding.
  • Propel Bio Management first reported a position in Inventiva in Q4 2025 and has held it in 3 quarters since.
  • 88 funds tracked by Wall St. Rank held Inventiva as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.